Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer

被引：0

作者：

Davide Melisi

Rocio Garcia-Carbonero

Teresa Macarulla

Denis Pezet

Gael Deplanque

Martin Fuchs

Jorg Trojan

Helmut Oettle

Mark Kozloff

Ann Cleverly

Claire Smith

Shawn T. Estrem

Ivelina Gueorguieva

Michael M. F. Lahn

Al Blunt

Karim A. Benhadji

Josep Tabernero

机构：

[1] University of Verona,Oncology Department

[2] Piazzale Ludovico Antonio Scuro,undefined

[3] Hospital Universitario 12 de Octubre,undefined

[4] Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12),undefined

[5] UCM,undefined

[6] CNIO,undefined

[7] CIBERONC,undefined

[8] Vall d’Hebron University Hospital Institute of Oncology (VHIO),undefined

[9] CIBERONC,undefined

[10] C/ Natzaret,undefined

[11] 115-117,undefined

[12] Centre Hospitalier Universitaire,undefined

[13] Hôpital Riviera-Chablais,undefined

[14] Klinikum Bogenhausen,undefined

[15] Städtisches Klinikum München GmbH,undefined

[16] Goethe University Medical Center,undefined

[17] Onkologische und Hämatologische Schwerpunktpraxis,undefined

[18] Ingalls Memorial Hospital,undefined

[19] Eli Lilly and Company,undefined

[20] Erl Wood Manor,undefined

[21] Windlesham,undefined

[22] formerly of Eli Lilly and Company,undefined

[23] Eli Lilly and Company,undefined

[24] Lilly Corporate Center,undefined

[25] 6820 Wisconsin Ave.,undefined

[26] #8008,undefined

[27] Advaxis,undefined

[28] Inc.,undefined

[29] Eli Lilly and Company,undefined

[30] Vall d’Hebron University Hospital and Institute of Oncology (VHIO),undefined

[31] CIBERONC,undefined

[32] Universitat Autònoma de Barcelona,undefined

[33] P. Vall d’Hebron 119-129,undefined

来源：

British Journal of Cancer | 2018年 / 119卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1208 / 1214

页数：6

共 50 条

[1] Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer
Melisi, Davide
Garcia-Carbonero, Rocio
Macarulla, Teresa
Pezet, Denis
Deplanque, Gael
Fuchs, Martin
Trojan, Jorg
Oettle, Helmut
Kozloff, Mark
Cleverly, Ann
Smith, Claire
Estrem, Shawn T.
Gueorguieva, Ivelina
Lahn, Michael M. F.
Blunt, Al
Benhadji, Karim A.
Tabernero, Josep
BRITISH JOURNAL OF CANCER, 2018, 119 (10) : 1208 - 1214
[2] Gemcitabine as first-line chemotherapy in elderly patients with unresectable pancreatic carcinoma
Yoshiyuki Yamagishi
Hajime Higuchi
Motoko Izumiya
Gen Sakai
Hideko Iizuka
Shoko Nakamura
Masayuki Adachi
Sigenari Hozawa
Hiromasa Takaishi
Toshifumi Hibi
Journal of Gastroenterology, 2010, 45 : 1146 - 1154
[3] Gemcitabine as first-line chemotherapy in elderly patients with unresectable pancreatic carcinoma
Yamagishi, Yoshiyuki
Higuchi, Hajime
Izumiya, Motoko
Sakai, Gen
Iizuka, Hideko
Nakamura, Shoko
Adachi, Masayuki
Hozawa, Sigenari
Takaishi, Hiromasa
Hibi, Toshifumi
JOURNAL OF GASTROENTEROLOGY, 2010, 45 (11) : 1146 - 1154
[4] Efficacy of nimotuzumab plus gemcitabine usage as first-line treatment in patients with advanced pancreatic cancer
Su, Dan
Jiao, Shun-Chang
Wang, Li-Jie
Shi, Wei-Wei
Long, Yan-Yan
Li, Juan
Bai, Li
TUMOR BIOLOGY, 2014, 35 (03) : 2313 - 2318
[5] A phase II, double-blind study of galunisertib plus gemcitabine (GG) vs gemcitabine plus placebo (GP) in patients (pts) with unresectable pancreatic cancer (PC)
Melisi, Davide
Garcia-Carbonero, Rocio
Macarulla, Teresa
Pezet, Denis
Deplanque, Gael
Fuchs, Martin
Trojan, Jorg
Oettle, Helmut
Kozloff, Mark
Cleverly, Ann
Gueorguieva, Ivelina
Desaiah, Durisala
Lahn, Michael M. F.
Blunt, Al
Benhadji, Karim A.
Tabernero, Josep
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[6] A phase II randomized trial of gemcitabine plus cisplatin(GP) vs. gemcitabine plus carboplatin (GC) as the first-line treatment for patients with metastatic triple negative breast cancer
Gong, Chengcheng
Cao, Enying
Wang, Zhonghua
Zhang, Jian
Wang, Leiping
Cao, Jun
Zhang, Sheng
Tao, Zhonghua
Li, Ting
Zhao, Yannan
Li, Yi
Wang, Biyun
Hu, Xichun
CANCER RESEARCH, 2018, 78 (04)
[7] Comparative effectiveness of gemcitabine vs gemcitabine plus nab-paclitaxel vs FOLFIRINOX for unresectable pancreatic cancer
Yamamoto, Shun
Ueno, Hideki
Tanaka, Midori
Inagaki, Yuji
Ohba, Akihiro
Sakamoto, Yasunari
Kondo, Shunsuke
Morizane, Chigusa
Okusaka, Takuji
ANNALS OF ONCOLOGY, 2017, 28
[8] Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure
Mita, Naoki
Iwashita, Takuji
Uemura, Shinya
Yoshida, Kensaku
Iwasa, Yuhei
Ando, Nobuhiro
Iwata, Keisuke
Okuno, Mitsuru
Mukai, Tsuyoshi
Shimizu, Masahito
JOURNAL OF CLINICAL MEDICINE, 2019, 8 (06)
[9] Erlotinib/gemcitabine improves survival in first-line pancreatic cancer patients
不详
ONCOLOGY-NEW YORK, 2004, 18 (11): : 1383 - 1383
[10] Gemcitabine confirmed as the first-line therapy for pancreatic cancer
Claire Greenhill
Nature Reviews Gastroenterology & Hepatology, 2011, 8 (1) : 3 - 3

← 1 2 3 4 5 →